Sign In

Cynthia Rothblum-Oviatt

Principal Consultant, RO Scientific / Science Advisor, Haystack Project

Cynthia Rothblum-Oviatt is a highly accomplished PhD scientist with 19 years of experience as a key opinion leader in the rare disease space. She has been instrumental in managing research strategies and coordinating research efforts for an international rare disease community. Cynthia holds a Doctor of Philosophy (Ph.D.) in Biochemistry from The George Washington University and a Bachelor of Arts (B.A.) in Biology, General from Washington and Jefferson College. Her extensive educational background has equipped her with a strong foundation in the scientific field.

Highlights

Feb 28 · linkedin

It is day three of Rare Disease Week! Please check out these guidance documents for rare disease drug development provided by the FDA. FDA’s guidance documents describe the agency’s current thinking on a topic and should be viewed as recommendations, unless specific regulatory or statutory requirements are cited. Guidance Documents for Rare Disease Drug Development | FDA Rare Diseases: Considerations for the Development of Drugs and Biological Products | FDA Demonstrating Substantial Evidence of Effectiveness With One Adequate and Well-Controlled Clinical Investigation and Confirmatory Evidence | FDA

Cynthia Rothblum-Oviatt
Add to my network

Location

Springfield, Virginia, United States